Protamine and Heparin Interactions: A Narrative Review

被引:8
作者
Crivellari, Martina [1 ]
Landoni, Giovanni [1 ,2 ]
Ursoleo, Jacopo D'Andria [1 ]
Ferrante, Luca [2 ]
Oriani, Alessandro [1 ]
机构
[1] IRCCS San Raffaele Sci Inst, Via Olgettina 60, I-20132 Milan, Italy
[2] Univ Vita Salute San Raffaele, Via Olgettina 58, I-20132 Milan, Italy
关键词
Activated clotting time; bleeding; cardiac anesthesia; cardiopulmonary bypass; coagulation; heparin; protamine; ACTIVATED CLOTTING TIME; EXTRACORPOREAL MEMBRANE-OXYGENATION; CARDIAC-SURGERY; COAGULATION; SULFATE; ANTICOAGULATION; ARTERIAL; REVERSAL; IMPACT; BYPASS;
D O I
10.4103/aca.aca_117_23
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Protamine, first isolated from salmon fish sperm and now produced through recombinant biotechnology, is an antidote that neutralizes the anticoagulant properties of heparin. Protamine function is based on the capacity to dissociate the heparin-antithrombin III (AT III) complex (an important link that promotes blood fluidification by inhibiting coagulation), forming the inactive heparin-protamine complex. Protamine has itself dose-dependent anticoagulant properties: It interferes with coagulation factors and platelet function; it stimulates fibrinolysis; it can lead to thrombocytopenia and reduction in thrombin-related platelet aggregation; it decreases platelet response to thrombin receptor agonist in a dose-dependent manner. In this review, we will focus on protamine and its interaction with heparin. Notably, protamine is able to antagonize not only unfractionated heparin (UFH) but also low molecular weight heparins to various degrees. Protamine-allergic and anaphylactoid systemic reactions may affect up to 1 in 10 people and should be prevented and treated early.
引用
收藏
页码:202 / 212
页数:11
相关论文
共 62 条
[41]  
Organization ECLS, 2014, Ann Arbor: Organization ECLS, P2
[42]  
Pesola GR, 1996, CATHETER CARDIO DIAG, V37, P140
[43]  
Ranucci M, 2002, Minerva Anestesiol, V68, P454
[44]   Different patterns of heparin resistance:: therapeutic implications [J].
Ranucci, M ;
Isgrò, G ;
Cazzaniga, A ;
Ditta, A ;
Boncilli, A ;
Cotza, M ;
Carboni, G ;
Brozzi, S .
PERFUSION-UK, 2002, 17 (03) :199-204
[45]  
Ranucci M, 2016, MINERVA ANESTESIOL, V82, P858
[46]  
RATH B, 1990, BRIT HEART J, V63, P18
[47]   Physiologically-Based Pharmacokinetic and Pharmacodynamic Modeling of Unfractionated Heparin to Predict Activated Clotting Time [J].
Regorda, Filippo ;
Vigoni, Emiliano ;
Pesenti, Giuseppe ;
Pieri, Marina ;
Belletti, Alessandro ;
Manca, Davide .
30TH EUROPEAN SYMPOSIUM ON COMPUTER AIDED PROCESS ENGINEERING, PTS A-C, 2020, 48 :703-708
[48]   Pharmacogenomics in the clinic [J].
Relling, Mary V. ;
Evans, William E. .
NATURE, 2015, 526 (7573) :343-350
[49]   Protamine neutralisation of low molecular weight heparins and their oligosaccharide components [J].
Schroeder, Mette ;
Hogwood, John ;
Gray, Elaine ;
Mulloy, Barbara ;
Hackett, Anne-Marie ;
Johansen, Kristian B. .
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2011, 399 (02) :763-771
[50]   Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping [J].
Shlensky, Julia A. ;
Thurber, Kristina M. ;
O'Meara, John G. ;
Ou, Narith N. ;
Osborn, Jennifer L. ;
Dierkhising, Ross A. ;
Mara, Kristin C. ;
Bierle, Dennis M. ;
Daniels, Paul R. .
VASCULAR MEDICINE, 2020, 25 (01) :47-54